Clinical Trial Update: Gemcitabine and Irinotecan in Treating Patients With Locally Advanced Unresectable or Metastatic Kidney Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating gemcitabine plus irinotecan in locally advanced unresectable or metastatic renal cell carcinoma was terminated; results were posted in …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Gemcitabine (Gemcitabine)
• Irinotecan (Irinotecan)

Snippet

Sponsor: Medical University of South Carolina | Conditions: Kidney Cancer | Phase 2 | Status: TERMINATED | Results posted: 2018-07-16